Abstract
AIMS
Diabetic gastroparesis is a common complication seen in 20-50% of patients due to autonomic neuropathy involving vagal supply. Cisapride, a specific gastrointestinal cholinomimetic agent may thus be effective.
METHODS
Fifty-one diabetic patients (age 12-65 years) of disease duration > 5 years were assessed for symptomatic gastroparesis, other diabetic complications and glycemic control. Gastric emptying time (GET) was estimated using a solid meal method (99mTc labeled rice based idli) and patients randomized to receive either cisapride or placebo for a period of 2 weeks. Cisapride was administered in a dose of 10 mg TID. GET and symptom scores were reassessed on the therapy after 2 weeks.
RESULTS
Twenty nine of 51 (56.8%) patients had gastroparesis. Mean GET in the gastroparesis group was 141 +/- 66 minutes compared to 24.53 +/- 10 minutes in the non gastroparesis group (p < 0.01). GET decreased by 72% amongst the patients who received cisapride compared to 23% in the placebo group (p < 0.001). Symptom scores also improved in the cisapride group; no adverse effects were noted.
CONCLUSIONS
Cisapride improves the symptom score and the solid gastric emptying time in patients suffering from diabetic gastroparesis.
TY - JOUR
T1 - Double blind controlled trial of effect of cisapride on gastric emptying in diabetics.
AU - Dutta,U,
AU - Padhy,A K,
AU - Ahuja,V,
AU - Sharma,M P,
PY - 2000/3/1/pubmed
PY - 2000/3/18/medline
PY - 2000/3/1/entrez
SP - 116
EP - 9
JF - Tropical gastroenterology : official journal of the Digestive Diseases Foundation
JO - Trop Gastroenterol
VL - 20
IS - 3
N2 - AIMS: Diabetic gastroparesis is a common complication seen in 20-50% of patients due to autonomic neuropathy involving vagal supply. Cisapride, a specific gastrointestinal cholinomimetic agent may thus be effective. METHODS: Fifty-one diabetic patients (age 12-65 years) of disease duration > 5 years were assessed for symptomatic gastroparesis, other diabetic complications and glycemic control. Gastric emptying time (GET) was estimated using a solid meal method (99mTc labeled rice based idli) and patients randomized to receive either cisapride or placebo for a period of 2 weeks. Cisapride was administered in a dose of 10 mg TID. GET and symptom scores were reassessed on the therapy after 2 weeks. RESULTS: Twenty nine of 51 (56.8%) patients had gastroparesis. Mean GET in the gastroparesis group was 141 +/- 66 minutes compared to 24.53 +/- 10 minutes in the non gastroparesis group (p < 0.01). GET decreased by 72% amongst the patients who received cisapride compared to 23% in the placebo group (p < 0.001). Symptom scores also improved in the cisapride group; no adverse effects were noted. CONCLUSIONS: Cisapride improves the symptom score and the solid gastric emptying time in patients suffering from diabetic gastroparesis.
SN - 0250-636X
UR - https://www.unboundmedicine.com/medline/citation/10695417/Double_blind_controlled_trial_of_effect_of_cisapride_on_gastric_emptying_in_diabetics_
L2 - https://medlineplus.gov/diabeticnerveproblems.html
DB - PRIME
DP - Unbound Medicine
ER -